Status:
COMPLETED
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer. ...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- locally advanced and/or metastatic pancreatic cancer (stage III or IV);
- Karnofsky performance Status of \>=60%.
Exclusion
- local(stage IA to IIB) pancreatic cancer;
- \<=6 months since last adjuvant chemotherapy;
- previous systemic therapy for metastatic pancreatic cancer;
- other primary tumor within last 5 years (except for adequately treated cancer in situ of cervix, or basal cell skin cancer);
- clinically significant cardiovascular disease.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT00461708
Start Date
May 1 2007
End Date
November 1 2010
Last Update
October 15 2015
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcoy, Alicante, Spain, 03804
2
Elche, Alicante, Spain, 03203
3
Palma de Mallorca, Balearic Islands, Spain, 07198
4
Barcelona, Barcelona, Spain, 08227